HUTCHMED to Announce 2024 Half-Year Financial Results
26 Giugno 2024 - 10:30AM
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13)
will be announcing its interim results for the six months ended
June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern
Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00
pm Hong Kong Time (HKT).
Analysts and investors are invited to join a
conference call and audio webcast presentation with Q&A,
conducted by HUTCHMED management.
The English conference call and audio webcast
will be held on Wednesday, July 31, 2024, at 8:00 am EDT (1:00 pm
BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at
8:30 am HKT / 1:30 am BST on Thursday, August 1, 2024 (8:30 pm EDT
on Wednesday, July 31, 2024). Both webcasts will be available live
via the company website at www.hutch-med.com/event/. The
presentation will be available for downloading before the
conference call begins. Details of the conference call dial-in will
be provided in the financial results announcement and on the
company website. A replay will also be available on the website
shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an
innovative, commercial-stage, biopharmaceutical company. It is
committed to the discovery and global development and
commercialization of targeted therapies and immunotherapies for the
treatment of cancer and immunological diseases. It has
approximately 5,000 personnel across all its companies, at the
center of which is a team of about 1,800 in oncology/immunology.
Since inception it has focused on bringing cancer drug candidates
from in-house discovery to patients around the world, with its
first three oncology drugs marketed in China, the first of which is
also marketed in the U.S. For more information, please visit:
www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries |
+852 2121 8200 / ir@hutch-med.com |
|
|
Media Enquiries |
|
Ben Atwell / Alex Shaw, FTI Consulting |
+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile) /
HUTCHMED@fticonsulting.com |
Zhou Yi, Brunswick |
+852 9783 6894 (Mobile) /
HUTCHMED@brunswickgroup.com |
|
|
Nominated Advisor |
|
Atholl Tweedie / Freddy Crossley / Rupert Dearden,
Panmure Gordon |
+44 (20) 7886 2500 |
Grafico Azioni HUTCHMED China (NASDAQ:HCM)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni HUTCHMED China (NASDAQ:HCM)
Storico
Da Nov 2023 a Nov 2024